The Service of the Commission for the Protection of Competition announces that it has received a notification of concentration by regarding the acquisition by Roche Holding AG of the share capital of companies constituting the TIB Group, through Roche Deutschland Holding GmbH and Roche Molecular Systems Inc. Pleasanton.
Roche Holding AG is the holding company of the Group of companies Roche, with shares listed on the Swiss Stock Exchange. Roche Group is one of the largest biotechnology companies in the world, active in pharmaceutical and diagnostic products with a focus on the progress of science in order to improve people's lives. The company also aims to improve patients' access to medical and medical products, by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization's Standard Lists of Essential Medicines, including antibiotics, malaria and anticancer drugs. In addition, Roche has been repeatedly recognized as one of the most viable companies in the pharmaceutical industry by the Dow Jones Sustainability Indicators. Roche operates under two departments: the Pharmaceutical Department and the Diagnostic Department.
TIB Group is a global biotechnology group that provides reagents for research and (molecular) medical diagnostics. TIB Group is active in the development, production and sale of oligonucleotides, as well as reagents/chemical tests ("reagents/assays") and kitsch for nucleic acid analysis and enhancement, especially in the fields ofnucleicacid analysis and enhancement, especially in the fields of research of life sciences and medical diagnosis. The portfolio of target companies includes PCR kitsch products and anadaptedoligonucleotides synthesis which are exclusively PCR reagents for open systems.